Preface to the First Edition of the *International Journal of Myeloma*

Kazuyuki SHIMIZU, MD, PhD

*The Chairman of the Board of Directors, The Japanese Society of Myeloma*

*The President of the 14th International Myeloma Workshop*

I am privileged to announce the publication of the first international journal focusing on multiple myeloma and its related disorders, from both basic and clinical point of view, which is given the name of *International Journal of Myeloma* following the great success of the 14th International Myeloma Workshop held in Kyoto, Japan, in April, 2013. *International Journal of Myeloma* is a peer-reviewed official journal of the Japanese Society of Myeloma and is published biannually. Endpoints of the publication of the *International Journal of Myeloma* are: (1) to serve as the platform for those expertising multiple myeloma around the world to network and present their latest research, clinical findings, practices, and the results of clinical trials including phase I/II studies of novel agents, (2) to publish a comprehensively written review updating and introducing the rapidly advancing understanding of the pathophysiology of myeloma including that of genetic and epigenetic background, as well as the most updated treatment strategy of myeloma, and (3) to serve also as the public relations of the Japanese Society of Myeloma.

I strongly urge the members of the Japanese Society of Myeloma to conduct clinical trials and publish the results in the *International Journal of Myeloma* to share the results with the readers and to further facilitate the acquisition of the treatment strategy which would result in best outcome.

I hope the *International Journal of Myeloma* would serve as the journal of dispatch of new information of myeloma for the clinicians and researchers studying myeloma world wide.